Comments
Loading...

Amicus Therapeutics

FOLDNASDAQ
Logo brought to you by Benzinga Data
$11.00
0.090.82%
At Close: -
$11.00
00.00%
After Hours: 4:46 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$22.00
Lowest Price Target1
$11.00
Consensus Price Target1
$16.15

Amicus Therapeutics (NASDAQ:FOLD) Stock, Analyst Ratings, Price Targets, Forecasts

Amicus Therapeutics Inc has a consensus price target of $16.15 based on the ratings of 14 analysts. The high is $22 issued by Cantor Fitzgerald on February 29, 2024. The low is $11 issued by Goldman Sachs on March 2, 2023. The 3 most-recent analyst ratings were released by Jefferies, JP Morgan, and Wells Fargo on September 6, 2024, August 16, 2024, and May 30, 2024, respectively. With an average price target of $17.33 between Jefferies, JP Morgan, and Wells Fargo, there's an implied 57.58% upside for Amicus Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
May
1
Aug
0
0
0
0
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Jefferies
JP Morgan
Wells Fargo
Guggenheim
UBS

1calculated from analyst ratings

Analyst Ratings for Amicus Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Amicus Therapeutics (FOLD) stock?

A

The latest price target for Amicus Therapeutics (NASDAQ:FOLD) was reported by Jefferies on September 6, 2024. The analyst firm set a price target for $18.00 expecting FOLD to rise to within 12 months (a possible 63.64% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Amicus Therapeutics (FOLD)?

A

The latest analyst rating for Amicus Therapeutics (NASDAQ:FOLD) was provided by Jefferies, and Amicus Therapeutics initiated their buy rating.

Q

When was the last upgrade for Amicus Therapeutics (FOLD)?

A

The last upgrade for Amicus Therapeutics Inc happened on May 14, 2024 when Guggenheim raised their price target to $13. Guggenheim previously had a neutral for Amicus Therapeutics Inc.

Q

When was the last downgrade for Amicus Therapeutics (FOLD)?

A

There is no last downgrade for Amicus Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Amicus Therapeutics (FOLD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amicus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amicus Therapeutics was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.

Q

Is the Analyst Rating Amicus Therapeutics (FOLD) correct?

A

While ratings are subjective and will change, the latest Amicus Therapeutics (FOLD) rating was a initiated with a price target of $0.00 to $18.00. The current price Amicus Therapeutics (FOLD) is trading at is $11.00, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch